We use cookies to improve the functionality and performance of this site. By continuing to use this site, you are providing us with your consent to our use of cookies on the site. Please see our Privacy Policy for details.

High Court Mulls Drugmakers' Liability in Preemption Case

BioWorldMarch 19, 2013

In Depth

William Gaede, speaking on an upcoming US Supreme Court case that will decide whether so-called pay-for-delay settlements with brand name drug companies that temporarily keep generic competitors out of the market are lawful in patent litigation, said that if the settlements (now a routine part of business plans for pharma companies) are upheld, they are likely to form the framework for future biosimilar litigation. Read the full article.